Alto Neuroscience (NYSE:ANRO) Shares Climb 7.6% – Here’s What Happened

Alto Neuroscience, Inc. (NYSE:ANRO)’s share price rose 7.6% during mid-day trading on Thursday. The stock traded as high as $32.52 and last traded at $33.5160. Approximately 131,380 shares were traded during trading, a decline of 70% from the average daily volume of 432,147 shares. The stock had previously closed at $31.15.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Zacks Research raised shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a report on Tuesday, October 27th. Wall Street Zen lowered shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Wedbush increased their target price on Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a research note on Thursday, August 13th. Finally, HC Wainwright reissued a “buy” rating on shares of Alto Neuroscience in a research note on Thursday. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.88.

Alto Neuroscience Trading Up 3.9%

The stock has a market capitalization of $1.27 billion, a P/E ratio of -13.26 and a beta of 1.42. The stock’s fifty day moving average price is $26.63 and its two-hundred day moving average price is $24.50. The company has a current ratio of 14.85, a quick ratio of 14.85 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Tuesday, November 10th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.13. Equities research analysts forecast that Alto Neuroscience, Inc. will post -2.69 EPS for the current year.

Insider Activity

In other news, CFO Nicholas Smith sold 110,830 shares of the firm’s stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $26.58, for a total transaction of $2,945,861.40. Following the transaction, the chief financial officer directly owned 24,060 shares of the company’s stock, valued at approximately $639,514.80. This trade represents a 82.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 11.25% of the company’s stock.

Institutional Investors Weigh In On Alto Neuroscience

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sterling Capital Management LLC grew its position in Alto Neuroscience by 1,045.7% during the 3rd quarter. Sterling Capital Management LLC now owns 1,054 shares of the company’s stock worth $27,000 after acquiring an additional 962 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Alto Neuroscience by 48,581.8% during the third quarter. Farther Finance Advisors LLC now owns 5,355 shares of the company’s stock valued at $137,000 after purchasing an additional 5,344 shares during the period. GK Wealth Management LLC bought a new position in shares of Alto Neuroscience in the second quarter worth approximately $226,000. The Manufacturers Life Insurance Company bought a new position in shares of Alto Neuroscience in the first quarter worth approximately $534,000. Finally, Bank of America Corp DE increased its stake in shares of Alto Neuroscience by 131.5% in the first quarter. Bank of America Corp DE now owns 25,677 shares of the company’s stock worth $577,000 after buying an additional 14,585 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.